Susceptibility of aerobic gram-negative bacilli to aminoglycosides: Effects of 45 months of amikacin as first-line aminoglycoside therapy
- 1 June 1986
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 80 (6) , 65-70
- https://doi.org/10.1016/0002-9343(86)90481-x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United StatesAntimicrobial Agents and Chemotherapy, 1985
- Aminoglycoside resistance in gram-negative bacilli during increased amikacin use: Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical CenterThe American Journal of Medicine, 1985
- Long-term Amikacin UsePublished by American Medical Association (AMA) ,1982
- Epidemiological studies of aminoglycoside resistance in the U.S.A.Journal of Antimicrobial Chemotherapy, 1981
- Emergence of Antibiotic Resistance In Hospitals, 1935-1975Clinical Infectious Diseases, 1979
- Significance of antimicrobial synergism for the outcome of gram negative sepsisThe Lancet Healthy Longevity, 1977
- Amikacin, an Aminoglycoside with Marked Activity against Antibiotic-Resistant Clinical IsolatesThe Journal of Infectious Diseases, 1976
- Gentamicin accumulation by sensitive strains of Escherichia coli and MPseudomonas aeruginosa.The Journal of Antibiotics, 1975
- Mechanisms and Spectrum of Streptomycin Resistance in a Natural Population of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1972
- R‐factor mediated gentamicin resistance: A new enzyme which modifies aminoglycoside antibioticsFEBS Letters, 1971